105 related articles for article (PubMed ID: 408150)
1. Total serum haemolytic complement activity, erythrocyte sedimentation rate and plasma fibrinogen as indicators of the stage in Hodgkin's disease.
Wagener DJ; Haanen C
Eur J Clin Invest; 1977 Aug; 7(4):289-94. PubMed ID: 408150
[TBL] [Abstract][Full Text] [Related]
2. Serum alpha-1-acid-glycoprotein, haptoglobin and C3 in Hodgkin's disease. A comparison with other acute-phase indicators.
Gobbi PG; Merlini G; Parrinello GA; Cavalli P; Ascari E
Acta Haematol; 1982; 67(4):255-62. PubMed ID: 6180585
[TBL] [Abstract][Full Text] [Related]
3. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease.
Seymour JF; Talpaz M; Hagemeister FB; Cabanillas F; Kurzrock R
Am J Med; 1997 Jan; 102(1):21-8. PubMed ID: 9209197
[TBL] [Abstract][Full Text] [Related]
4. [Significance of metabolic parameters in Hodgkin's disease (author's transl)].
Oertel J; Gerhartz H
Z Krebsforsch Klin Onkol Cancer Res Clin Oncol; 1976 Jun; 86(2):185-93. PubMed ID: 59479
[TBL] [Abstract][Full Text] [Related]
5. Serum copper compared to erythrocyte sedimentation rate as indicator of disease activity in Hodgkin's disease.
Asbjörnsen G
Scand J Haematol; 1979 Mar; 22(3):193-6. PubMed ID: 451449
[TBL] [Abstract][Full Text] [Related]
6. Serum copper, serum ceruloplasmin, and erythrocyte sedimentation rate measurements in children with Hodgkin's disease, non-Hodgkin's lymphoma, and nonmalignant lymphadenopathy.
Margerison AC; Mann JR
Cancer; 1985 Apr; 55(7):1501-6. PubMed ID: 3978543
[TBL] [Abstract][Full Text] [Related]
7. Plasma activity inducing polymorphonuclear neutrophils (PMN) aggregation, chemotactic plasma activity, and plasma activity augmenting PMN adherence in untreated patients with Hodgkin's disease. Possible relationship to disseminated intravascular complement activation.
Wierusz-Wysocka B; Wysocki H
Oncology; 1984; 41(6):409-13. PubMed ID: 6504496
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of erythrocyte sedimentation rate in clinical stages I-II of Hodgkin's disease.
Tubiana M; Henry-Amar M; Burgers MV; van der Werf-Messing B; Hayat M
J Clin Oncol; 1984 Mar; 2(3):194-200. PubMed ID: 6366151
[TBL] [Abstract][Full Text] [Related]
9. [Relation between hematic fibrinogen and sedimentation rate of erythrocytes in Hodgkin's disease, reticulosarcoma and lymphosarcoma].
Girolami A
Riv Crit Clin Med; 1965 Jun; 65(3):344-9. PubMed ID: 5326288
[No Abstract] [Full Text] [Related]
10. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
Bien E; Balcerska A
Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
[TBL] [Abstract][Full Text] [Related]
11. [Risk factors for bone marrow involvement in Hodgkin's disease].
Kanaev SV; Novikov SN; Zhukova LA; Pozharisskiĭ KM; Leenman EE; Gershanovich ML
Vopr Onkol; 2001; 47(1):39-44. PubMed ID: 11317533
[TBL] [Abstract][Full Text] [Related]
12. The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre.
Howell SJ; Grey M; Chang J; Morgenstern GR; Cowan RA; Deakin DP; Radford JA
Br J Haematol; 2002 Nov; 119(2):408-11. PubMed ID: 12406078
[TBL] [Abstract][Full Text] [Related]
13. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance.
Gobbi PG; Ghirardelli ML; Solcia M; Di Giulio G; Merli F; Tavecchia L; Bertè R; Davini O; Levis A; Broglia C; Maffè GC; Ilariucci F; Dore R; Ascari E
J Clin Oncol; 2001 Mar; 19(5):1388-94. PubMed ID: 11230483
[TBL] [Abstract][Full Text] [Related]
14. Circulating immune complexes, complement and complement component levels in childhood Hodgkin's disease.
Brandeis WE; Tan C; Wang Y; Good RA; Day NK
Clin Exp Immunol; 1980 Mar; 39(3):551-61. PubMed ID: 7379328
[TBL] [Abstract][Full Text] [Related]
15. Value of serum copper levels and erythrocyte sedimentation rates as indicators of disease activity in children with Hodgkin's disease.
Wilimas J; Thompson E; Smith KL
Cancer; 1978 Oct; 42(4):1929-35. PubMed ID: 709539
[TBL] [Abstract][Full Text] [Related]
16. Precipitable immune complexes in Hodgkin's disease.
Euler HH; Béress R; Moldenhauer I; Löffler H
Int J Cancer; 1983 Oct; 32(4):437-41. PubMed ID: 6618706
[TBL] [Abstract][Full Text] [Related]
17. Red blood cell survival in patients with Hodgkin's disease.
Lanaro AE; Bosch A; Frĭas Z
Cancer; 1971 Sep; 28(3):658-61. PubMed ID: 5096930
[No Abstract] [Full Text] [Related]
18. Serum concentrations of cytokines in patients with Hodgkin's disease.
Blay JY; Farcet JP; Lavaud A; Radoux D; Chouaïb S
Eur J Cancer; 1994; 30A(3):321-4. PubMed ID: 8204352
[TBL] [Abstract][Full Text] [Related]
19. [Significance of some humoral and cytological indices in active stages of Hodgkin's disease].
Barbui T; Dini E; Chisesi T; Corà R; Franchi F; Cazzavillan M; Battista R
Haematologica; 1972; 57(9):488-92. PubMed ID: 4125445
[No Abstract] [Full Text] [Related]
20. Hodgkin's disease: a quantitative evaluation by computed tomography of tumor burden.
Torricelli P; Grimaldi PL; Fiocchi F; Federico M; Romagnoli R
Clin Imaging; 2004; 28(4):239-44. PubMed ID: 15246472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
